GSK stays strong as healthy sales beat expectations
By Natalie Grover and Maggie Fick LONDON (Reuters) -GSK began 2023 with a quarterly performance that beat analyst expectations and extended a series of positive results thanks to strong sales of its vaccines as well as HIV and respiratory medicines. The company reaffirmed its guidance for 2023, saying it expected adjusted operating profit growth to…
